Stenner-Liewen et al. [40] carried out a phase IIb, double-blinded, randomized placebo-controlled trial in patients with histologically confirmed prostate cancer in patients with a PSA ≥ 5 ng/mL; this used an amount of pomegranate active principle per day (20 mg in 500 mL), which was only 5% of that investigated in the other studies [41]. The gene discussed is KLK3; the disease is prostate carcinoma.